等待開盤 01-29 09:30:00 美东时间
-0.490
-0.67%
Makarora Management LP and Ares Alternative Credit funds have completed the acquisition of Plymouth Industrial REIT, Inc. in an all-cash transaction valued at approximately $2.1 billion. Plymouth shareholders will receive $22.00 per share, and the company will no longer be listed on any public exchange. KeyBanc Capital Markets and J.P. Morgan served as financial advisors for Plymouth, while Morrison & Foerster and Alston & Bird were legal counsel...
01-27 20:33
U.S. RESEARCH ROUNDUP-CACI International, First Citizens Bancshares, Teledyne Technologies Jan 26 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including CACI International, First Citizens Bancshares and Teledyne Technologies, o
01-26 15:22
Allied Gold Corporation has agreed to be acquired by Zijin Gold International Company Limited for C$44 per share in cash, valued at approximately C$5.5 billion. The offer represents a 27% premium over Allied Gold’s 30-day VWAP on the TSX. Zijin Gold, a major global mining firm, aims to expand its African presence through this transaction. The deal is subject to shareholder and regulatory approvals and is expected to close by late April 2026. Alli...
01-26 11:00
今日重点评级关注:Needham:维持Vaxcyte"买入"评级,目标价从90美元升至110美元;Citizens: 维持LGI Homes"跑赢大市"评级,目标价从85美元升至95美元
01-08 18:33
今日重点评级关注:HC Wainwright & Co.:维持MetaVia Inc."买入"评级,目标价从12美元升至40美元;Canaccord Genuity:维持GH Research"买入"评级,目标价从35美元升至39美元
01-07 17:25
Morgan Stanley analyst Ryan Kenny maintains Moelis (NYSE:MC) with a Overweight and raises the price target from $86 to $89.
01-06 23:39
今日重点评级关注:巴克莱:维持Iovance Biotherapeutics"超配"评级,目标价从9美元升至10美元;摩根大通:上调Recursion Pharmaceuticals评级至"超配",目标价从10美元升至11美元
2025-12-18 10:54
今日重点评级关注:HC Wainwright & Co.:维持Moleculin Biotech"买入"评级,目标价从4美元升至22美元;HC Wainwright & Co.:上调Soluna Holdings评级至"买入",目标价5美元
2025-12-12 10:24
UBS analyst Michael Brown assumes Moelis (NYSE:MC) with a Neutral rating and announces Price Target of $70.
2025-12-11 23:33
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Moelis业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** - 2025年第三季度调整后营收为3.76亿美元,同比增长34% - 2025年前九个月调整后营收达到10.5亿美元,同比增长37% - 营收增长主要由M&A和资本市场业务驱动,但被资本结构咨询业务下滑部分抵消 **业务结构:** - 第三季度和前九个月业务组合均为:约三分之二来自M&A业务,三分之一来自非M&A业务 **利润率表现:** - 第三季度调整后税前利润率为22.2% - 前九个月调整后税前利润率为18.2%,管理层称这是"相比去年同期的显著改
2025-10-31 12:20